EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Strategies for Performing Factor Assays in the Presence of Emicizumab or Other Novel/Emerging Hemostatic Agents

Geoffrey Kershaw

Seminars in Thrombosis and Hemostasis · 01.11.2024 · 50 (08) · 1163-1172

DOI: 10.1055/s-0044-1787189 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Thrombosis and Hemostasis, erschienen am 01.11.2024. Verfasst von Geoffrey Kershaw. Beteiligte Einrichtung: Institute of Haematology, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW, Australia. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Hemostatics. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For several decades, therapeutic options for inherited deficiencies of factor VIII or IX (hemophilia A or B, respectively) have largely been the replacement of the missing clotting factor with plasma-derived or recombinant products. Hemostasis laboratories use standard activated partial thromboplastin time (aPTT)-based clotting or chromogenic assays to monitor plasma factor levels to guide therapy. The emergence in the past 10 years of extended half-life replacement products and other novel therapies for hemophilia has led to a reappraisal of assay suitability, with studies of product measurement showing some existing assay types or reagents to be unsuitable for some products. The hemostasis laboratory must adapt to the changing landscape by adding new assays or modifying existing assays to ensure accurate results for product measurement. These strategies include switching from a chromogenic assay to a clotting assay, or vice versa, changing an aPTT reagent brand, or introducing product specific calibrators. This article evaluates the effects of some of the newer treatment options on the laboratory testing of factor levels and related assays.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificAntibodies, Monoclonal, HumanizedHemostaticsHumansHemophilia ABlood Coagulation TestsPartial Thromboplastin Time

Substanzen

emicizumabAntibodies, BispecificAntibodies, Monoclonal, HumanizedHemostatics

Autor:innen und Institutionen

  • Institute of Haematology, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW, Australia.
  • ANZAC Research Institute, University of Sydney, Hospital Road, Concord, NSW, Australia.

Zitieren

APA

Kershaw, G. (2024). Strategies for Performing Factor Assays in the Presence of Emicizumab or Other Novel/Emerging Hemostatic Agents. Seminars in Thrombosis and Hemostasis, 50(08), 1163-1172. https://doi.org/10.1055/s-0044-1787189

Vancouver

Kershaw G. Strategies for Performing Factor Assays in the Presence of Emicizumab or Other Novel/Emerging Hemostatic Agents. Seminars in Thrombosis and Hemostasis. 2024;50(08):1163-1172. doi:10.1055/s-0044-1787189

BibTeX
@article{Kershaw2024,
  author = {Kershaw, Geoffrey},
  title = {Strategies for Performing Factor Assays in the Presence of Emicizumab or Other Novel/Emerging Hemostatic Agents},
  journal = {Seminars in Thrombosis and Hemostasis},
  year = {2024},
  volume = {50},
  number = {08},
  pages = {1163--1172},
  doi = {10.1055/s-0044-1787189}
}
Kostenlos starten →